• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

澳大利亚糖尿病、肥胖和生活方式研究的数据对四种心血管风险预测模型的外部验证和比较。

External validation and comparison of four cardiovascular risk prediction models with data from the Australian Diabetes, Obesity and Lifestyle study.

机构信息

Centre for Research in Evidence-Based Practice, Bond University, Gold Coast, QLD.

Baker IDI Heart and Diabetes Institute, Melbourne, VIC.

出版信息

Med J Aust. 2019 Mar;210(4):161-167. doi: 10.5694/mja2.12061. Epub 2019 Jan 18.

DOI:10.5694/mja2.12061
PMID:30656697
Abstract

OBJECTIVES

To evaluate the performance of the 2013 Pooled Cohort Risk Equation (PCE-ASCVD) for predicting cardiovascular disease (CVD) in an Australian population; to compare this performance with that of three frequently used Framingham-based CVD risk prediction models.

DESIGN

Prospective national population-based cohort study.

SETTING

42 randomly selected urban and non-urban areas in six Australian states and the Northern Territory.

PARTICIPANTS

5453 adults aged 40-74 years enrolled in the Australian Diabetes, Obesity and Lifestyle study and followed until November 2011. We excluded participants who had CVD at baseline or for whom data required for risk model calculations were missing.

MAIN OUTCOME MEASURES

Predicted and observed 10-year CVD risks (adjusted for treatment drop-in); performance (calibration and discrimination) of four CVD risk prediction models: 1991 Framingham, 2008 Framingham, 2008 office-based Framingham, 2013 PCE-ASCVD.

RESULTS

The performance of the 2013 PCE-ASCVD model was slightly better than 1991 Framingham, and each was better the two 2008 Framingham risk models, both in men and women. However, all four models overestimated 10-year CVD risk, particularly for patients in higher deciles of predicted risk. The 2013 PCE-ASCVD (7.5% high risk threshold) identified 46% of men and 18% of women as being at high risk; the 1991 Framingham model (20% threshold) identified 17% of men and 2% of women as being at high risk. Only 16% of men and 11% of women identified as being at high risk by the 2013 PCE-ASCVD experienced a CV event within 10 years.

CONCLUSIONS

The 2013 PCE-ASCVD or 1991 Framingham should be used as CVD risk models in Australian. However, the CVD high risk threshold for initiating CVD primary preventive therapy requires reconsideration.

摘要

目的

评估 2013 年 pooled cohort risk equation(PCE-ASCVD)在澳大利亚人群中预测心血管疾病(CVD)的性能;并与三种常用的基于Framingham 的 CVD 风险预测模型进行比较。

设计

前瞻性全国人群队列研究。

地点

澳大利亚六个州和北领地的 42 个随机选择的城市和非城市地区。

参与者

澳大利亚糖尿病、肥胖和生活方式研究中招募的 5453 名年龄在 40-74 岁之间的成年人,随访至 2011 年 11 月。我们排除了基线时患有 CVD 或需要计算风险模型数据的参与者。

主要结局指标

预测和观察到的 10 年 CVD 风险(调整治疗中断);四种 CVD 风险预测模型的性能(校准和区分):1991 年Framingham、2008 年Framingham、2008 年基于办公室的Framingham、2013 年 PCE-ASCVD。

结果

2013 年 PCE-ASCVD 模型的性能略优于 1991 年Framingham,在男性和女性中,每个模型都优于两个 2008 年Framingham 风险模型。然而,所有四个模型都高估了 10 年 CVD 风险,特别是在预测风险较高的患者中。2013 年 PCE-ASCVD(7.5%高风险阈值)确定 46%的男性和 18%的女性为高风险;1991 年Framingham 模型(20%的阈值)确定 17%的男性和 2%的女性为高风险。只有 16%的男性和 11%的女性被 2013 年 PCE-ASCVD 识别为高风险,但在 10 年内经历了 CV 事件。

结论

在澳大利亚,应使用 2013 年 PCE-ASCVD 或 1991 年Framingham 作为 CVD 风险模型。然而,需要重新考虑启动 CVD 一级预防治疗的 CVD 高风险阈值。

相似文献

1
External validation and comparison of four cardiovascular risk prediction models with data from the Australian Diabetes, Obesity and Lifestyle study.澳大利亚糖尿病、肥胖和生活方式研究的数据对四种心血管风险预测模型的外部验证和比较。
Med J Aust. 2019 Mar;210(4):161-167. doi: 10.5694/mja2.12061. Epub 2019 Jan 18.
2
External validation and clinical usefulness of three commonly used cardiovascular risk prediction scores in an Emirati population: a retrospective longitudinal cohort study.在阿联酋人群中对三种常用心血管风险预测评分进行外部验证和临床实用性评估:一项回顾性纵向队列研究。
BMJ Open. 2020 Oct 28;10(10):e040680. doi: 10.1136/bmjopen-2020-040680.
3
Performance of the Pooled Cohort Equations to Estimate Atherosclerotic Cardiovascular Disease Risk by Body Mass Index.基于体重指数的 pooled cohort equations 评估动脉粥样硬化性心血管疾病风险的性能。
JAMA Netw Open. 2020 Oct 1;3(10):e2023242. doi: 10.1001/jamanetworkopen.2020.23242.
4
Temporal trends in cardiovascular risk factors and performance of the Framingham Risk Score and the Pooled Cohort Equations.心血管危险因素的时间趋势及 Framingham 风险评分和 Pooled Cohort 方程的表现。
J Epidemiol Community Health. 2019 Jan;73(1):19-25. doi: 10.1136/jech-2018-211102. Epub 2018 Sep 27.
5
Validation of Risk Prediction Models for Atherosclerotic Cardiovascular Disease in a Prospective Korean Community-Based Cohort.前瞻性韩国社区队列中动脉粥样硬化性心血管疾病风险预测模型的验证。
Diabetes Metab J. 2020 Jun;44(3):458-469. doi: 10.4093/dmj.2019.0061. Epub 2020 Jan 13.
6
Cardiovascular Risk Prediction Functions Underestimate Risk in HIV Infection.心血管风险预测模型在 HIV 感染中的风险预测存在偏差。
Circulation. 2018 May 22;137(21):2203-2214. doi: 10.1161/CIRCULATIONAHA.117.028975. Epub 2018 Feb 14.
7
External validation of three atherosclerotic cardiovascular disease risk equations in rural areas of Xinjiang, China.中国新疆农村地区三个动脉粥样硬化性心血管疾病风险方程的外部验证
BMC Public Health. 2020 Sep 29;20(1):1471. doi: 10.1186/s12889-020-09579-4.
8
Cardiovascular risk prediction in a population with the metabolic syndrome: Framingham vs. UKPDS algorithms.代谢综合征人群的心血管风险预测:弗明汉算法与英国前瞻性糖尿病研究(UKPDS)算法
Eur J Prev Cardiol. 2014 Mar;21(3):384-90. doi: 10.1177/2047487312449307. Epub 2012 May 15.
9
Cardiovascular disease risk prediction in sub-Saharan African populations - Comparative analysis of risk algorithms in the RODAM study.撒哈拉以南非洲人群的心血管疾病风险预测 - RODAM 研究中风险算法的比较分析。
Int J Cardiol. 2018 Mar 1;254:310-315. doi: 10.1016/j.ijcard.2017.11.082. Epub 2018 Jan 28.
10

引用本文的文献

1
Discrimination and calibration performances of non-laboratory-based and laboratory-based cardiovascular risk predictions: a systematic review.基于非实验室和基于实验室的心血管风险预测的辨别和校准性能:一项系统评价。
Open Heart. 2025 Feb 10;12(1):e003147. doi: 10.1136/openhrt-2024-003147.
2
Comparing predictive risk to actual presence of coronary atherosclerosis on coronary computed tomography angiography.在冠状动脉计算机断层扫描血管造影中比较预测风险与冠状动脉粥样硬化的实际存在情况。
Am Heart J Plus. 2024 Dec 6;49:100493. doi: 10.1016/j.ahjo.2024.100493. eCollection 2025 Jan.
3
Comparison of atherosclerotic cardiovascular disease (ASCVD) and Framingham risk scores (FRS) in an Iranian population.
伊朗人群中动脉粥样硬化性心血管疾病(ASCVD)与弗雷明汉风险评分(FRS)的比较。
Int J Cardiol Cardiovasc Risk Prev. 2024 May 24;21:200287. doi: 10.1016/j.ijcrp.2024.200287. eCollection 2024 Jun.
4
Major Limitations of Cardiovascular Risk Scores.心血管风险评分的主要局限性。
Cardiovasc Ther. 2024 Feb 28;2024:4133365. doi: 10.1155/2024/4133365. eCollection 2024.
5
Cardiovascular Disease Risk Scores and Incident Dementia and Cognitive Decline in Older Men and Women.心血管疾病风险评分与老年男女的痴呆和认知能力下降的关系。
Gerontology. 2024;70(2):143-154. doi: 10.1159/000535284. Epub 2023 Nov 20.
6
Evidence supporting the choice of a new cardiovascular risk equation for Australia.支持为澳大利亚选择新心血管风险方程的证据。
Med J Aust. 2023 Aug 21;219(4):173-186. doi: 10.5694/mja2.52052. Epub 2023 Jul 26.
7
An Assessment of the Effect of Bariatric Surgery on Cardiovascular Disease Risk in the Chinese Population Using Multiple Cardiovascular Risk Models.使用多种心血管风险模型评估减重手术对中国人群心血管疾病风险的影响
Diabetes Metab Syndr Obes. 2023 Apr 12;16:1029-1042. doi: 10.2147/DMSO.S389346. eCollection 2023.
8
Projecting the Health and Economic Burden of Cardiovascular Disease Among People with Type 2 Diabetes, 2022-2031.预测 2022-2031 年 2 型糖尿病患者心血管疾病的健康和经济负担。
Pharmacoeconomics. 2023 Jun;41(6):719-732. doi: 10.1007/s40273-023-01258-7. Epub 2023 Mar 21.
9
Sex-Specific Survival Bias and Interaction Modeling in Coronary Artery Disease Risk Prediction.性别特异性生存偏差与冠状动脉疾病风险预测中的交互作用建模。
Circ Genom Precis Med. 2023 Feb;16(1):e003542. doi: 10.1161/CIRCGEN.121.003542. Epub 2022 Dec 29.
10
Development and internal validation of the Edmonton Obesity Staging System-2 Risk screening Tool (EOSS-2 Risk Tool) for weight-related health complications: a case-control study in a representative sample of Australian adults with overweight and obesity.开发和内部验证埃德蒙顿肥胖分期系统-2 风险筛查工具(EOSS-2 Risk Tool)用于与体重相关的健康并发症:在超重和肥胖的澳大利亚成年人代表性样本中的病例对照研究。
BMJ Open. 2022 Jun 22;12(6):e061251. doi: 10.1136/bmjopen-2022-061251.